NOT medical advice. Always consult a healthcare professional. NOT affiliated with or endorsed by the NHS, NHSBSA, MHRA, or any government body.

NOT medical advice. Always consult a qualified healthcare professional. NOT affiliated with, or endorsed by the NHS, NHSBSA, MHRA, or any government body.

NOT medical advice. Always consult a qualified healthcare professional. NOT affiliated with, or endorsed by the NHS, NHSBSA, MHRA, or any government body.

Emergency?Call 999

Need NHS advice?Call 111

Loading...

Prasugrel 10mg tablets | findmeds.uk™

Prasugrel 10mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

10mg

Oral

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine.

Active ingredients:

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 02.09

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC B01AC22

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Prasugrel

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Prasugrel

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Prasugrel

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Prasugrel

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

21 branded products available

21 productsShow details

21 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Prasugrel on the MHRA register

Efient 10mg tablets

Efient 10mg tablets

Prasugrel 10mg tablets

Prasugrel 10mg tablets

Prasugrel 10mg tablets

Viatris UK Healthcare Ltd

Prasugrel 10mg tablets

A A H Pharmaceuticals Ltd

Prasugrel 10mg tablets

Alliance Healthcare (Distribution) Ltd

Prasugrel 10mg tablets

Sovereign Medical Ltd

Prasugrel 10mg tablets

Prasugrel 10mg tablets

Thornton & Ross Ltd

Prasugrel 10mg tablets

Medihealth (Northern) Ltd

Prasugrel 10mg tablets

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£2.88indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

10 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Treprostinil 10mg/10ml solution for infusion vials

Same therapeutic group

Treprostinil 100mg/10ml solution for infusion vials

Same therapeutic group

Treprostinil 25mg/10ml solution for infusion vials

Same therapeutic group

Treprostinil 50mg/10ml solution for infusion vials

Same therapeutic group

Treprostinil 200mg/20ml solution for infusion vials

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Prasugrel

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(8)

Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)

Technology appraisal

Updated Jul 2014

Acute coronary syndromes (NG185)

Updated Nov 2020

Coronary revascularisation: Cangrelor (ESNM63)

Evidence summary

Updated Nov 2015

Ticagrelor for the treatment of acute coronary syndromes (TA236)

Technology appraisal

Updated Oct 2011

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Technology appraisal

Updated Mar 2015

Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)

Updated Aug 2020

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Technology appraisal

Updated Dec 2016

Head injury: assessment and early management (NG232)

Updated May 2023

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

Pharmacy2U

Search products

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Prasugrel

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

39702811000001103

dm+d ID

39702811000001103

VTM (Virtual Therapeutic Moiety)

777298009

VMP (Virtual Medicinal Product)

39702811000001103

BNF code

02090000

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

B01AC22

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

152 found

Half-life

7.4 hours

Mechanism

Prasugrel is an thienopyridine and a prodrug which inhibits ADP receptors by irr…

Food interactions

2 warnings

Human targets

1 target

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

79%

79% or greater of the dose is absorbed after oral administration.…

Half-life

7.4 hours

The active metabolite has an elimination half-life of about 7.4 hours (range 2-15 hours).

Protein binding

98%

Approximately 98% of the active metabolite was bound to human serum albumin in a 4% buffered solution.…

Volume of distribution

44-68L

44-68L

Metabolism

Prasugrel is not detected in plasma following oral administration.…

Elimination

68%

Approximately 68% of the orally administered dose is excreted in urine and 27% in the feces, as inactive metabolites.…

Clearance

112 - 166 L/h

Apparent clearance = 112 - 166 L/hr

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Properties:

solid

Avg. mass: 373.44 Da

View FDA drug label

DrugBank indication

Indicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.

Also known as(58)

Prasugrel

ADP-glucose receptor

ADPG-R

HORK3

P2T(AC)

P2Y(AC)

P2Y(ADP)

P2Y(cyc)

Dosage forms(15)

Tablet (Oral) — 10 mg

Tablet (Oral) — 5.000 mg

Tablet, coated (Oral) — 10 mg/1

Tablet, coated (Oral) — 5 mg/1

Tablet, film coated (Oral) — 10 mg/1

Tablet, film coated (Oral) — 4.12 Mg

Tablet, film coated (Oral) — 5.49 Mg

Tablet, coated (Oral) — 10 mg

Molecular properties(19)

Drug interactions(1379)

Known interactions with other medications. Always consult a healthcare professional.

Moderate

Apixaban may increase the anticoagulant activities of Prasugrel.

Check this interaction

Dabigatran etexilate

Moderate

Dabigatran etexilate may increase the anticoagulant activities of Prasugrel.

Check this interaction

Major

The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Prasugrel.

Check this interaction

Unknown severity

The risk or severity of gastrointestinal bleeding can be increased when Prasugrel is combined with Deferasirox.

Check this interaction

Unknown severity

The risk or severity of bleeding can be increased when Edoxaban is combined with Prasugrel.

Check this interaction

Major

The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Prasugrel.

Check this interaction

Moderate

Prasugrel may increase the anticoagulant activities of Rivaroxaban.

Check this interaction

Major

The risk or severity of bleeding and hemorrhage can be increased when Prasugrel is combined with Sugammadex.

Check this interaction

Moderate

Tibolone may increase the anticoagulant activities of Prasugrel.

Check this interaction

Moderate

Urokinase may increase the anticoagulant activities of Prasugrel.

Check this interaction

Major

The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Prasugrel.

Check this interaction

Ursodeoxycholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Ursodeoxycholic acid.

Check this interaction

Glycochenodeoxycholic Acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Glycochenodeoxycholic Acid.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Cholic Acid.

Check this interaction

Glycocholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Glycocholic acid.

Check this interaction

Deoxycholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Deoxycholic acid.

Check this interaction

Taurocholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Taurocholic acid.

Check this interaction

Obeticholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Obeticholic acid.

Check this interaction

Chenodeoxycholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Chenodeoxycholic acid.

Check this interaction

Taurochenodeoxycholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Taurochenodeoxycholic acid.

Check this interaction

Tauroursodeoxycholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Tauroursodeoxycholic acid.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Bamet-UD2.

Check this interaction

Dehydrocholic acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Dehydrocholic acid.

Check this interaction

Hyodeoxycholic Acid

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Hyodeoxycholic Acid.

Check this interaction

Moderate

Glucosamine may increase the antiplatelet activities of Prasugrel.

Check this interaction

Ibritumomab tiuxetan

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Prasugrel is combined with Obinutuzumab.

Check this interaction

Moderate

Tipranavir may increase the antiplatelet activities of Prasugrel.

Check this interaction

Moderate

Vitamin E may increase the antiplatelet activities of Prasugrel.

Check this interaction

Moderate

Ginkgo biloba may increase the anticoagulant activities of Prasugrel.

Check this interaction

Unknown severity

The risk or severity of bleeding can be increased when Ifosfamide is combined with Prasugrel.

Check this interaction

Moderate

The therapeutic efficacy of Prasugrel can be increased when used in combination with Quinine.

Check this interaction

Moderate

The therapeutic efficacy of Prasugrel can be increased when used in combination with Quinidine.

Check this interaction

Unknown severity

The risk or severity of bleeding can be increased when Tamoxifen is combined with Prasugrel.

Check this interaction

Unknown severity

The risk or severity of bleeding can be increased when Toremifene is combined with Prasugrel.

Check this interaction

Moderate

The therapeutic efficacy of Prasugrel can be increased when used in combination with Pentoxifylline.

Check this interaction

Moderate

Cangrelor may decrease the antiplatelet activities of Prasugrel.

Check this interaction

Pentosan polysulfate

Unknown severity

The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Prasugrel.

Check this interaction

Moderate

The therapeutic efficacy of Prasugrel can be increased when used in combination with Levocarnitine.

Check this interaction

Diethylstilbestrol

Moderate

Diethylstilbestrol may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Chlorotrianisene

Moderate

Chlorotrianisene may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Conjugated estrogens

Moderate

Conjugated estrogens may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Unknown severity

The risk or severity of adverse effects can be increased when Mestranol is combined with Prasugrel.

Check this interaction

Estrone sulfate

Moderate

Estrone sulfate may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Moderate

Quinestrol may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Moderate

Hexestrol may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Synthetic Conjugated Estrogens, A

Moderate

Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Synthetic Conjugated Estrogens, B

Moderate

Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Polyestradiol phosphate

Moderate

Polyestradiol phosphate may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Esterified estrogens

Moderate

Esterified estrogens may decrease the anticoagulant activities of Prasugrel.

Check this interaction

Showing 50 of 1379 interactions

Food & lifestyle interactions

Advice

Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Advice

Take with or without food.

Toxicity & overdose

LD50 (rat) 1,000 - 2,000 mg/kg; LD50 (rabbit) > 1,000 mg/kg

How it works

Mechanism of action

Prasugrel is an thienopyridine and a prodrug which inhibits ADP receptors by irreversibly acting on the P2Y12 receptor on platelets. The active metabolite of prasugrel prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Prasugrel is proposed to have a similar mechanism of action to clopidogrel.

Pharmacodynamics

Prasugrel is a thienopyridine ADP receptor inhibitors which inhibits platelet aggregation by irreversibly binding to P2Y12 receptors.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

79% or greater of the dose is absorbed after oral administration. Absorption and metabolism occur rapidly and peak plasma concentrations (C_max) are reached approximately 30 minutes following oral administration. Administration with a high fat, high calorie meal did not affect the AUC of the active metabolite in healthy individuals, but the C_max was decreased by ~49% and the T_max was increased to 0.5 to 1.5 hours.

Prasugrel may be administered with or without food.

Half-life

The active metabolite has an elimination half-life of about 7.4 hours (range 2-15 hours).

Protein binding

Approximately 98% of the active metabolite was bound to human serum albumin in a 4% buffered solution. The major inactive metabolites are also highly bound to human plasma proteins.

Volume of distribution

44-68L

Metabolism

Prasugrel is not detected in plasma following oral administration. It is rapidly hydrolyzed in the intestine to thiolactone by human carboxylesterase (hCE) 2. This intermediate is further metabolized to its active metabolite, R-138727, in a single step by cytochrome P450 enzymes in the liver (primarily CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19).

The active metabolite is further metabolized by S-methylation or cysteine conjugation to two inactive metabolites.

Unlike clopidogrel, transformation of prasugrel to its active metabolite does not appear to be affected by cytochrome P450 polymorphisms.

Route of elimination

Approximately 68% of the orally administered dose is excreted in urine and 27% in the feces, as inactive metabolites. The active metabolite is not expected to be removed by dialysis.

Clearance

Apparent clearance = 112 - 166 L/hr

Drug targets(1)

Proteins and enzymes this drug interacts with in the body

P2Y purinoceptor 12

P2RY12

antagonist

Specific functionG protein-coupled adenosine receptor activity

Cellular location

Cell membrane

General function & pharmacology

Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation

Metabolizing enzymes(5)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CES2Cocaine esterase

substrate

CYP3A4Cytochrome P450 3A4

substrate

CYP2B6Cytochrome P450 2B6

substrate

CYP2C9Cytochrome P450 2C9

substrate

CYP2C19Cytochrome P450 2C19

substrate

Carriers(1)

Proteins that carry this drug through the body

Albumin

ALB

substrate

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Scientific references(4)

Dovlatova N.L., Jakubowski J.A., Sugidachi A., Heptinstall S.

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function.

Journal of Thrombosis and Haemostasis

2008 Jul6(7):1153-9. doi: 10.1111/j.1538-7836.2008.03020.x. Epub 2008 Jul 1

PMID: 18485086 DOI: 10.1111/j.1538-7836.2008.03020.x

Tagarakis G.I.

Ticagrelor and Prasugrel: Two Novel, Most-Promising Antiplatelet Agents.

Recent Patents on Cardiovascular Drug Discovery

20105(3):208-211. doi: 10.2174/157489010793351908

PMID: 20874669 DOI: 10.2174/157489010793351908

Angiolillo D.J.

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

Drugs

2012 Nov 1272(16):2087-116. doi: 10.2165/11640880-000000000-00000

PMID: 23083110 DOI: 10.2165/11640880-000000000-00000

Jeong Y.H., Tantry U.S., Gurbel P.A.

Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.

Expert Opinion on Pharmacotherapy

2012 Aug13(12):1771-96. doi: 10.1517/14656566.2012.704909. Epub 2012 Jul 12

PMID: 22783896 DOI: 10.1517/14656566.2012.704909

ATC classification(1 code)

ATC B01AC22

Affected organisms(1)

Humans and other mammals

International brands(1)

Salt forms(2)

Prasugrel besylate(DBSALT003141)

Prasugrel hydrochloride(DBSALT000145)

Experimental properties(1)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(78)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Prasugrel

CAS number

150322-43-3

UNII (FDA)

34K66TBT99

InChI Key (molecular fingerprint)

DTGLZDAWLRGWQN-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

20588

ChEBI

87723

PubChem Compound

6918456

PubChem Substance

99443238

KEGG Drug

D05597

ChemSpider

5293653

PharmGKB

PA154410481

Wikipedia

Prasugrel

ChEMBL

CHEMBL1201772

RxCUI

613391

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18124

GenAtlas

P2RY12

GeneCards

P2RY12

GenBank Gene Database

AF313449

GenBank Protein Database

12083902

IUPHAR

328

Guide to Pharmacology

328

UniProtKB

Q9H244

UniProt Accession

P2Y12_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1864

GeneCards

CES2

Guide to Pharmacology

3298

UniProtKB

O00748

UniProt Accession

EST2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

Patent information

All patents expired, 5 expired

United States

Paediatric ext.

Approved 26 Mar 2013 · Expires 2 Jul 2023

Expired

United States

Paediatric ext.

Approved 29 Oct 2013 · Expires 2 Jul 2023

Expired

United States

Approved 17 Feb 2004 · Expires 3 Jul 2021

Expired

United States

Paediatric ext.

Approved 22 Feb 1994 · Expires 14 Oct 2017

Expired

Canada

Approved 20 Aug 2002 · Expires 8 Sept 2012

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines